Search Results
Advantages and limitations of ruxolitinib for cGvHD
Limitations of ibrutinib and ruxolitinib use in cGVHD
Ibrutinib, ruxolitinib & belumosudil for SR-cGvHD
Approval of Ruxolitinib: Steroid-Refractory Acute GVHD
Mechanisms of action of ibrutinib, ruxolitinib, and belumosudil, and their role in cGvHD treatment
Case 3: Ruxolitinib for Steroid-Refractory Acute GVHD
Overcoming GVHD Is the Key to Better HCT Outcomes: Guidance on Managing Acute and Chronic Disease
News from ASH 2020: 'Practice-changing' results with ruxolitinib in chronic GVHD
Recent advances in the management of cGvHD
REACH3 study: Should ruxolitinib become SoC for steroid-dependent or refractory chronic GvHD?
INDICATIONS AND IMPORTANT SAFETY INFORMATION for Jakafi® (ruxolitinib)
Overcoming the Challenges of Acute and Chronic GVHD
